Centrida is an innovative interventional medical device company specializing in interventional treatment without implantation and thrombus aspiration for vascular diseases. The company innovatively developed a fat-soluble peripheral paclitaxel drug balloon with magnesium stearate as the drug carrier.
In 2016, the company developed and launched China's first peripheral DCB product, leading the second place for about four years. In terms of revenue in 2020, the company's market share in China's peripheral DCB market exceeded 86.9%, occupying a dominant position. The company's second DCB product was designated as a "breakthrough device" by FDA in 2019 and approved by NMPA in December 2020, making it the world's first (currently the only) BTK DCB product based on the results of multicenter randomized controlled clinical trials.
The company has a comprehensive layout of a number of large vascular areas, expanding DCB indications for arteriovenous fistula (AVF) stenosis; developing radiofrequency ablation catheters in the field of varicose veins; and developing thrombus aspiration catheters in the field of deep venous thrombosis.
The DCB track where the company's current products are sold is just in its infancy in China, and Ruida is the first company in China to get a license. In addition, the company also develops a comprehensive product line covering five areas of treatment, which can provide a full range of vascular intervention without implantation solutions. With solid product clinical performance, good working relationship with KOL and hospitals, large distributor network, rich experience accumulated from existing commercial activities, and good reputation in China and the global medical device industry market, the company has become a large, fast-growing and not yet fully infiltrated global leader in the medical device industry in China. To sum up, a variety of efforts to promote the development of the company, it is suggested to actively pay attention to.
Risk hints: product indications are not approved in time; market competition intensifies; risk of policy change.